Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official Title: A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo.
In Brief: Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
Ages Eligible: 18 Years to 70 Years
Start Date: September 25, 2019
Completion Date (estimated): July 2020
Status: Active, recruiting
- ClinicalTrials.gov: NCT04103060
- Other Study ID Numbers: DMVT-502-2101
Location: Dermavant Investigational Site: Worcester, Massachusetts, United States, 01605
Contact: To learn more about this study, you or your doctor may contact Dermavant Sciences by phone +1-480-666-0844 or email firstname.lastname@example.org. Please refer to this study by its ClinicalTrials.gov identifier (NCT number)
- Who is prone to vitiligo?
Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...
- Shall I take vitamin D for my vitiligo?
In Brief Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be id...
- Is it Bitiligo? Vitaligo? Veteligo?
There are so many different ways that people try and spell or even pronounce Vitiligo. Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vita...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.